Product
anti-PD1
1 clinical trial
2 indications
Indication
Melanoma stage IIIIndication
MelanomaClinical trial
A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.Status: Recruiting, Estimated PCD: 2027-01-01